Article Figures & Data
Figures
- FIG. 1.
Flow cytometry histograms showing the respiratory-burst (RB) profiles of five different dilutions of positive S2 serum sample 659 (A to E) and one dilution of S1 serum sample 12 with low activity (F). The histograms are gated on the PMN population in a two-parameter dot plot of forward versus side scatter histograms to discriminate lymphocytes, monocytes, and PMNs (not shown). The horizontal bar defines the area of RB-positive cells, and the value above the bar is the percentage of positive PMNs. S2 serum sample 659 had an OPA titer of 256, whereas S1 serum sample 12 had a titer of <4. Overlaid in panel F is a profile of a negative control sample, i.e., dilution buffer instead of test serum (stippled histogram).
- FIG. 2.
Distribution of OPA titers and corresponding anti-PT IgG levels. The bars represent the number of samples at each OPA titer, and the diamonds reflect the geometric mean Serion PT IgG level at each OPA titer. All serum samples, both S1 and S2, are included.
Tables
- TABLE 1.
Serion anti-PT IgG levels in paired serum samples collected from all participantsa
Sample groupb (no. of samples) Geometric mean activity (FDA U/ml)d S1 S2 1 (361) 6.0 (5.6, 6.5) 4.8 (4.5, 5.2) 2c (64) 37.8 (31.7, 45.2) 37.4 (33.5, 41.8) 3 (39) 165.4 (142.3, 192.3) 100.0 (82.9, 120.5) ↵a Samples were collected at entry into military service (S1) and 8 months later (S2). Paired serum samples were grouped on the basis of Serion PT IgG activity.
↵b Serion PT IgG levels were as follows: for group 1, <30 FDA U/ml in both S1 and S2; for group 2, 30 to 80 FDA U/ml in S1 and/or S2; and for group 3, >80 FDA U/ml in S1.
↵c Also included in group 2 is the one subject with seroconversion during service (reaching 103.0 FDA U/ml in the S2 sample).
↵d Values in parentheses are 95% CIs.
- TABLE 2.
Geometric mean activities measured by the different assaysa
Sample group (no. of samples)b Geometric mean activity (95% CI) Serion PT IgG (FDA U/ml) Pert FHA IgG (% of cutoff) Pert FHA IgA (% of cutoff) Pert PT IgG (% of cutoff) Pert PT IgA (% of cutoff) OPA against live bacteria (titer) C3b against live bacteria (AU/ml) IgG against live bacteria (AU/ml) 1 (92) 4.9 (4.1, 5.9) 126.1 (113.1, 140.4) 54.6 (49.3, 60.6) 101.0 (92.1, 110.8) 82.5 (76.6, 88.8) 49.2 (38.1, 63.5) 232.6 (206.0, 262.6) 62.6 (50.1, 78.3) 2 (89) 47.7 (45.2, 50.5) 246.6 (229.1, 265.5) 92.0 (80.1, 105.7) 267.4 (255.4, 279.9) 80.5 (75.2, 86.2) 227.8 (185.8, 279.2) 520.3 (435.8, 621.1) 375.4 (291.6, 483.2) 3 (67) 150.9 (135.3, 168.1) 309.5 (283.5, 337.9) 125.8 (108.0, 146.4) 491.8 (466.2, 518.7) 91.4 (83.8, 99.8) 429.4 (343.6, 536.7) 1,031.0 (799.2, 1,330.0) 843.4 (620.4, 1,146.0) - TABLE 3.
Correlation between different assays of the 248 serum samples testeda
Test Pearson's correlation coefficient (r) with: Serion PT IgG Pertusscan FHA IgG Pertusscan FHA IgA Pertusscan PT IgG Pertusscan PT IgA IgG against live bacteria OPA against live bacteria Pertusscan FHA IgG 0.72 Pertusscan FHA IgA 0.51 0.65 Pertusscan PT IgG 0.95 0.72 0.53 Pertusscan PT IgA 0.14b 0.19c 0.49 0.25 IgG live bacteria 0.67 0.72 0.56 0.68 0.22d OPA live bacteria 0.68 0.79 0.64 0.69 0.27 0.83 C3b live bacteria 0.59 0.52 0.47 0.61 0.21e 0.76 0.70
